About Our Lab
Cancer is a diverse and heterogeneous disease, hence one therapy will not be uniformly beneficial to all patients. To dissect heterogeneity at the molecular level, we employ multi-omics analysis on data generated from patient tumors. We implement integrated bioinformatic approaches to understand the role of mutations, structural variations, gene expressions, genomic alterations, proteomic and phospho-proteomic signatures in promoting cancer or driving drug resistance. Our research lab focuses on improving cancer diagnosis, treatment and survival by employing data science in precision medicine.
Meenakshi Anurag
Lab News
- Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
- The importance of a biomarker-directed approach in triple-negative breast cancer (video)
- LIG1 deletion predicts chemotherapy resistance in triple-negative breast cancer (video)
- Treatments for HR+ postmenopausal breast cancer (video)
- OCCPR Webinar: Translational Discovery and Validation Using Multi-omics Data from ER+ Breast Tumors (video)
- Meenakshi Anurag on Breast Cancer: New Data on Combining Anastrozole and Fulvestrant






